Phenotypic data from 296,307 participants enrolled in SPARK, including 117,203 individuals with ASD, are now available to approved researchers. Genomic data (whole-exome sequencing and genome-wide genotyping data) are also available for 81,172 SPARK participants. Of these, 3,568 genomes and 34,164 exomes are from individuals with ASD.

Clinical Research Associates, L.L.C., an affiliate of the Simons Foundation, has recently launched a randomized controlled trial to test the safety, tolerability and efficacy of arbaclofen in 16p11.2 BP4-BP5 deletion syndrome.

In a series of articles published in the journal Nature Genetics, researchers used data from the SPARK research cohort, which was created to advance our understanding of the complex genetics of autism and includes genetic data from nearly 43,000 people with autism. The findings show differences in genetic influences among people all along the autism spectrum.

SFARI is pleased to announce that it has selected seven fellows in response to the 2022 Bridge to Independence Award request for applications.

New phenotypic data from Simons Searchlight participants were recently added to SFARI Base. This release includes data from individuals with 59 gene changes and nine copy number variants known to be connected to autism.

SFARI is pleased to announce that it intends to fund four grants in response to the request for applications (RFA) focused on the analysis of postmortem brain tissue from the Autism BrainNet collection.

SFARI is pleased to support the Summer Undergraduate Research Program in 2022, working with SFARI Investigators and leading U.S. universities to help provide opportunities for undergraduate students to gain research experience in autism science.

RNA-sequencing data from lymphoblastoid cell lines derived from individuals with ASD and their unaffected siblings from the Simons Simplex Collection are now available to approved researchers.